HRP20020537A2 - Ep4 receptor selective agonists in the treatment of osteoporosis - Google Patents
Ep4 receptor selective agonists in the treatment of osteoporosis Download PDFInfo
- Publication number
- HRP20020537A2 HRP20020537A2 HRP20020537A HRP20020537A2 HR P20020537 A2 HRP20020537 A2 HR P20020537A2 HR P20020537 A HRP20020537 A HR P20020537A HR P20020537 A2 HRP20020537 A2 HR P20020537A2
- Authority
- HR
- Croatia
- Prior art keywords
- phenyl
- pyrrolidin
- butyl
- hydroxy
- oxo
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/20—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Physical Education & Sports Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17135399P | 1999-12-22 | 1999-12-22 | |
| PCT/IB2000/001711 WO2001046140A1 (en) | 1999-12-22 | 2000-11-20 | Ep4 receptor selective agonists in the treatment of osteoporosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20020537A2 true HRP20020537A2 (en) | 2004-12-31 |
Family
ID=22623430
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20020537 HRP20020537A2 (en) | 1999-12-22 | 2000-11-20 | Ep4 receptor selective agonists in the treatment of osteoporosis |
Country Status (36)
Families Citing this family (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20010056060A1 (en) * | 2000-02-07 | 2001-12-27 | Cameron Kimberly O. | Treatment of osteoporsis with EP2/EP4 receptor selective agonists |
| MXPA03004623A (es) | 2000-11-27 | 2003-09-05 | Pfizer Prod Inc | Agonistas selectivos del receptor ep4 en el tratamiento de la osteoporosis. |
| KR100702368B1 (ko) | 2001-07-16 | 2007-04-02 | 에프. 호프만-라 로슈 아게 | 프로스타노이드 작용제로서의 2 피롤리돈 유도체 |
| DE60208568T2 (de) * | 2001-07-16 | 2006-10-05 | F. Hoffmann-La Roche Ag | Prostaglandinanaloga als ep4-rezeptoragonisten |
| ATE500218T1 (de) * | 2001-07-23 | 2011-03-15 | Ono Pharmaceutical Co | Mittel zur behandlung von erkrankungen, die mit knochenschwund einhergehen, mit ep4-agonist als wirkstoff |
| ES2360604T3 (es) * | 2001-07-23 | 2011-06-07 | Ono Pharmaceutical Co., Ltd. | Remedios para enfermedades con pérdida de masa osea que tienen como ingrediente activo agonistas de ep4. |
| WO2003041717A1 (fr) * | 2001-11-12 | 2003-05-22 | Ono Pharmaceutical Co., Ltd. | Preparation pelliculaire persistante pour administration localisee contenant un derive de prostaglandine |
| US20040254230A1 (en) * | 2001-12-03 | 2004-12-16 | Ogidigben Miller J. | Method for treating ocular hypertension |
| JP2005519879A (ja) * | 2001-12-03 | 2005-07-07 | メルク エンド カムパニー インコーポレーテッド | Ｅｐ４受容体作動剤とその組成物および方法 |
| AU2002358772B2 (en) * | 2001-12-20 | 2008-11-20 | Merck Serono Sa | Pyrrolidine derivatives as prostaglandin modulators |
| BR0308166A (pt) | 2002-03-05 | 2005-01-18 | Ono Pharmaceutical Co | Compostos de derivados de 8-azaprostaglandina e drogas contendo os compostos como o ingrediente ativo |
| EP1490055A1 (en) * | 2002-03-18 | 2004-12-29 | Pfizer Products Inc. | Use of selective ep4 receptor agonists for the treatment of liver failure, loss of patency of the ductus arteriosus, glaucoma or ocular hypertension |
| US6573294B1 (en) | 2002-05-14 | 2003-06-03 | Allergan, Inc. | 8-azaprostaglandin analogs as agents for lowering intraocular pressure |
| AU2011202937B2 (en) * | 2002-05-14 | 2012-06-07 | Allergan, Inc. | 8-azaprostaglandin analogs as agents for lowering intraocular pressure |
| JP4766875B2 (ja) | 2002-06-06 | 2011-09-07 | メルク フロスト カナダ リミテツド | Ｅｐ４受容体作動薬、組成物及びその方法 |
| EP1556347A4 (en) * | 2002-06-10 | 2006-08-09 | Applied Research Systems | GAMMA LACTAME AS PROSTAGLAND INAGONISTS AND THEIR USE |
| EP1563846B1 (en) | 2002-10-10 | 2012-08-29 | Ono Pharmaceutical Co., Ltd. | Endogenous repair factor production promoters |
| AU2003287481B2 (en) | 2002-11-08 | 2009-04-23 | Merck & Co., Inc. | Ophthalmic compositions for treating ocular hypertension |
| US7196082B2 (en) | 2002-11-08 | 2007-03-27 | Merck & Co. Inc. | Ophthalmic compositions for treating ocular hypertension |
| US7053085B2 (en) | 2003-03-26 | 2006-05-30 | Merck & Co. Inc. | EP4 receptor agonist, compositions and methods thereof |
| BRPI0406717A (pt) | 2003-01-10 | 2005-12-20 | Hoffmann La Roche | Composto, composição farmacêutica que compreende o mesmo, método de tratamento de uma enfermidade em um mamìfero, utilização do composto e processo para a sua produção |
| US7256211B1 (en) | 2003-01-21 | 2007-08-14 | Ono Pharmaceutical Co., Ltd. | 8-azaprostaglandin derivatives and medical use thereof |
| ES2305779T3 (es) | 2003-03-03 | 2008-11-01 | Laboratoires Serono Sa | Derivados de g-lactama como agonistas de prostaglandinas. |
| US6734206B1 (en) * | 2003-06-02 | 2004-05-11 | Allergan, Inc. | 3-oxa-8-azaprostaglandin analogs as agents for lowering intraocular pressure |
| US6734201B1 (en) | 2003-06-02 | 2004-05-11 | Allergan, Inc. | 8-Azaprostaglandin carbonate and thiocarbonate analogs as therapeutic agents |
| US7179820B2 (en) | 2003-06-06 | 2007-02-20 | Allergan, Inc. | Piperidinyl prostaglandin E analogs |
| EP1654219A2 (en) | 2003-07-18 | 2006-05-10 | Applied Research Systems ARS Holding N.V. | Hydrazide derivatives as prostaglandin receptors modulators |
| AU2004268012B2 (en) | 2003-09-02 | 2008-11-20 | Merck & Co., Inc. | Ophthalmic compositions for treating ocular hypertension |
| CA2537430A1 (en) | 2003-09-04 | 2005-03-24 | Merck & Co., Inc. | Ophthalmic compositions for treating ocular hypertension |
| CN1845904A (zh) | 2003-09-04 | 2006-10-11 | 默克公司 | 用于治疗高眼压的眼用组合物 |
| WO2005027931A1 (en) * | 2003-09-19 | 2005-03-31 | Pfizer Products Inc. | Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and an ep2 or ep4 selective agonist |
| US7326732B2 (en) | 2004-02-12 | 2008-02-05 | Pharmagene Laboratories Limited | EP2 receptor agonists |
| CN1988903A (zh) | 2004-07-20 | 2007-06-27 | 默克公司 | 用于治疗高眼压症的眼用组合物 |
| DE602005019090D1 (de) | 2004-12-06 | 2010-03-11 | Merck Serono Sa Coinsins | Pyrrolidin-2-on-Derivate zur Verwendung als DP1-Rezeptoragonisten |
| US7531533B2 (en) | 2005-01-27 | 2009-05-12 | Asahi Kasei Pharma Corporation | 6-Membered heterocyclic compound and use thereof |
| EP1878429B1 (en) | 2005-04-28 | 2011-08-03 | Ono Pharmaceutical Co., Ltd. | Trenadermal absorption preparation |
| KR100686186B1 (ko) * | 2005-06-13 | 2007-02-26 | 영진종합건설 주식회사 | 교량용 배수 구조물 |
| CA2618486A1 (en) | 2005-08-09 | 2007-02-15 | Asterand Uk Limited | Ep2 receptor agonists |
| WO2008050848A1 (fr) | 2006-10-26 | 2008-05-02 | Ono Pharmaceutical Co., Ltd. | Préparation adhésive |
| EP2094839B1 (en) | 2006-12-08 | 2020-02-05 | University of Rochester | Expansion of hematopoietic stem cells |
| US20090124695A1 (en) | 2007-11-14 | 2009-05-14 | Cayman Chemical Company | Prostaglandin e1 and e2 analogs for the treatment of various medical conditions |
| CA2738045C (en) | 2010-05-28 | 2019-02-19 | Simon Fraser University | Conjugate compounds, methods of making same, and uses thereof |
| AU2012290987B2 (en) | 2011-08-02 | 2017-04-20 | Ono Pharmaceutical Co., Ltd. | Left ventricular diastolic function improving agent |
| HRP20170045T1 (hr) | 2012-07-19 | 2017-03-10 | Cayman Chemical Company, Incorporated | Difluorlaktamski spojevi kao selektivni agonisti ep4 receptora za uporabu za liječenje bolesti i stanja posredovanih s ep4 receptorom |
| ES2733998T3 (es) | 2012-10-29 | 2019-12-03 | Cardio Incorporated | Agente terapéutico específico de enfermedad pulmonar |
| US9676712B2 (en) | 2013-03-15 | 2017-06-13 | Cayman Chemical Company, Inc. | Lactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions |
| US9688627B2 (en) * | 2013-03-15 | 2017-06-27 | Cayman Chemical Company, Inc. | Lactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions |
| CA2910398A1 (en) | 2013-07-19 | 2015-01-22 | Cayman Chemical Company, Inc. | Methods, systems, and compositions for promoting bone growth |
| KR20220147691A (ko) | 2013-08-09 | 2022-11-03 | 알데릭스, 인코포레이티드 | 인산염 수송을 억제하기 위한 화합물 및 방법 |
| WO2015056504A1 (ja) | 2013-10-15 | 2015-04-23 | 小野薬品工業株式会社 | 薬剤溶出性ステントグラフト |
| EP3307747A4 (en) | 2015-06-12 | 2019-02-27 | Simon Fraser University | AMID LINKED EP4 AGONIST BISPHOSPHONATE COMPOUNDS AND USES THEREOF |
| WO2020237096A1 (en) | 2019-05-21 | 2020-11-26 | Ardelyx, Inc. | Combination for lowering serum phosphate in a patient |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR897566A (fr) | 1942-08-28 | 1945-03-26 | Bopp & Reuther Gmbh | Machine à rotors |
| US3528961A (en) | 1966-08-16 | 1970-09-15 | Allied Chem | Monoazo dyes from e-caprolactam |
| US3780095A (en) | 1970-04-08 | 1973-12-18 | Byk Gulden Lomberg Chem Fab | Acylated anilino-carboxylic acids and their salts |
| US3987091A (en) | 1973-04-12 | 1976-10-19 | Merck & Co., Inc. | 11,12-secoprostaglandins |
| US4033996A (en) | 1973-04-25 | 1977-07-05 | Merck & Co., Inc. | 8-Aza-9-oxo(and dioxo)-thia-11,12-secoprostaglandins |
| SE7414770L (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1973-12-13 | 1975-06-16 | Merck & Co Inc | |
| DK366475A (da) | 1974-08-30 | 1976-03-01 | Merck & Co Inc | Fremgangsmade til fremstilling af aryloxy- eller arylthioholdige secoprostaglandiner |
| US3991106A (en) | 1974-09-13 | 1976-11-09 | Merck & Co., Inc. | 16-Ethers of 8-aza-9-dioxothia-11,12-seco-prostaglandins |
| US4055596A (en) | 1974-09-13 | 1977-10-25 | Merck & Co., Inc. | 11,12-Seco-prostaglandins |
| US4113873A (en) | 1975-04-26 | 1978-09-12 | Tanabe Seiyaku Co. Ltd. | 8-azaprostanoic acid derivatives |
| DE2528664A1 (de) * | 1975-06-27 | 1977-01-13 | Hoechst Ag | Pyrrolidone und verfahren zu ihrer herstellung |
| IL49325A (en) | 1976-03-31 | 1979-11-30 | Labaz | 8-aza-11-deoxy-pge1 derivatives,their preparation and pharmaceutical compositions containing them |
| DE2619638A1 (de) * | 1976-05-04 | 1977-11-17 | Hoechst Ag | Pyrrolidone und verfahren zu ihrer herstellung |
| US4177346A (en) | 1976-08-06 | 1979-12-04 | Pfizer Inc. | 1,5-Disubstituted-2-pyrrolidones |
| US4175203A (en) | 1976-12-17 | 1979-11-20 | Merck & Co., Inc. | Interphenylene 11,12-secoprostaglandins |
| US4243678A (en) | 1977-12-30 | 1981-01-06 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Acylhydrocarbylaminoalkanoic acids, compositions and uses |
| DE3000377A1 (de) | 1980-01-07 | 1981-07-09 | Boehringer Mannheim Gmbh, 6800 Mannheim | Neue sulfonamide, verfahren zu deren herstellung sowie diese verbindungen enthaltende arzneimittel |
| DE3042482A1 (de) | 1980-11-11 | 1982-06-24 | A. Nattermann & Cie GmbH, 5000 Köln | N-benzoyl- (omega) -anilinoalkancarbonsaeuren, -salze und -ester, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische praeparate |
| CA1214170A (fr) | 1981-06-16 | 1986-11-18 | Patrick Choay | Procedes de preparation de nouveaux composes du type arylbenzenesulfonamide |
| AU6427596A (en) * | 1992-04-14 | 1996-10-31 | Alfred Maximillian Stessl | A boat hull |
| TW383306B (en) | 1992-12-22 | 2000-03-01 | Lilly Co Eli | New use of 2-phenyl-3-aroylbenzothiophenes in lowering serum cholesterol |
| ATE390917T1 (de) * | 1996-12-20 | 2008-04-15 | Pfizer | Prävention und behandlung von skeletterkrankungen mit ep2 subtyp selektiven prostaglandin e2 agonisten |
| GB2330307A (en) * | 1998-02-07 | 1999-04-21 | Glaxo Group Ltd | EP4 Receptor antagonists as bone resorption inhibitors |
| EP1148877A4 (en) * | 1998-10-15 | 2003-01-22 | Merck & Co Inc | METHOD FOR INHIBITING BONE RESORPTION |
| JP2002527400A (ja) * | 1998-10-15 | 2002-08-27 | メルク エンド カムパニー インコーポレーテッド | 骨形成刺激方法 |
-
2000
- 2000-11-20 OA OA1200200177A patent/OA12117A/en unknown
- 2000-11-20 AP APAP/P/2001/002357A patent/AP2001002357A0/en unknown
- 2000-11-20 AU AU12931/01A patent/AU1293101A/en not_active Abandoned
- 2000-11-20 UA UA2002065186A patent/UA72293C2/uk unknown
- 2000-11-20 SK SK855-2002A patent/SK8552002A3/sk unknown
- 2000-11-20 EA EA200200505A patent/EA005293B1/ru not_active IP Right Cessation
- 2000-11-20 WO PCT/IB2000/001711 patent/WO2001046140A1/en active Application Filing
- 2000-11-20 HR HRP20020537 patent/HRP20020537A2/hr not_active Application Discontinuation
- 2000-11-20 EE EEP200200355A patent/EE200200355A/xx unknown
- 2000-11-20 PL PL00356662A patent/PL356662A1/xx not_active Application Discontinuation
- 2000-11-20 AP APAP/P/2002/002555A patent/AP2002002555A0/en unknown
- 2000-11-20 GE GEAP20006502A patent/GEP20043203B/en unknown
- 2000-11-20 TR TR2002/01643T patent/TR200201643T2/xx unknown
- 2000-11-20 BR BR0016560-3A patent/BR0016560A/pt not_active IP Right Cessation
- 2000-11-20 MX MXPA02006322A patent/MXPA02006322A/es active IP Right Grant
- 2000-11-20 CN CN00817566A patent/CN1413190A/zh active Pending
- 2000-11-20 CZ CZ20022048A patent/CZ20022048A3/cs unknown
- 2000-12-11 AT AT00311034T patent/ATE250575T1/de not_active IP Right Cessation
- 2000-12-11 DK DK00311034T patent/DK1110949T3/da active
- 2000-12-11 EP EP00311034A patent/EP1110949B1/en not_active Expired - Lifetime
- 2000-12-11 TR TR2003/01841T patent/TR200301841T4/xx unknown
- 2000-12-11 DE DE60005471T patent/DE60005471T2/de not_active Expired - Fee Related
- 2000-12-11 PT PT00311034T patent/PT1110949E/pt unknown
- 2000-12-11 ES ES00311034T patent/ES2204458T3/es not_active Expired - Lifetime
- 2000-12-14 IL IL14032500A patent/IL140325A0/xx unknown
- 2000-12-15 US US09/738,670 patent/US6737437B2/en not_active Expired - Fee Related
- 2000-12-19 PE PE2000001368A patent/PE20010953A1/es not_active Application Discontinuation
- 2000-12-19 KR KR10-2000-0078214A patent/KR100419681B1/ko not_active Expired - Fee Related
- 2000-12-20 CA CA002329678A patent/CA2329678A1/en not_active Abandoned
- 2000-12-20 AU AU72393/00A patent/AU763983B2/en not_active Ceased
- 2000-12-20 ZA ZA200007694A patent/ZA200007694B/xx unknown
- 2000-12-21 HU HU0005001A patent/HUP0005001A3/hu unknown
- 2000-12-22 CO CO00097391A patent/CO5251453A1/es not_active Application Discontinuation
- 2000-12-22 JP JP2000390594A patent/JP2001181210A/ja not_active Ceased
-
2001
- 2001-11-16 US US09/991,585 patent/US6642266B2/en not_active Expired - Fee Related
-
2002
- 2002-05-17 IS IS6388A patent/IS6388A/is unknown
- 2002-06-12 CR CR6678A patent/CR6678A/es not_active Application Discontinuation
- 2002-06-13 MA MA26686A patent/MA26852A1/fr unknown
- 2002-06-18 NO NO20022925A patent/NO20022925L/no not_active Application Discontinuation
- 2002-06-28 BG BG106882A patent/BG106882A/xx unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20020537A2 (en) | Ep4 receptor selective agonists in the treatment of osteoporosis | |
| ES2291361T3 (es) | Agonistas selectivos del receptor ep4 en el tratamiento de la osteoporosis. | |
| US6376502B1 (en) | Osteoporosis compounds | |
| HRP980356A2 (en) | Prostaglandin agonists | |
| US20010056060A1 (en) | Treatment of osteoporsis with EP2/EP4 receptor selective agonists | |
| AU2008291814A1 (en) | Polymorphs of 3- ( ( (4-tert-butyl-benzyl) - (pyridine-3-sulfonyl) -amino) -methyl) -phenoxy) -acetic acid sodium salt or a hydrate thereof and methods for making the same | |
| HK1051366A (en) | Ep4 receptor selective agonists in the treatment of osteoporosis | |
| WO2009027803A2 (en) | Polymorphs of (3-(((4-tert-butyl-benzyl)-(pyridine-3-sulfonyl)-amino)-methyl)- phenoxy)-acetic acid, free acid |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A1OB | Publication of a patent application | ||
| OBST | Application withdrawn |